DBD
Diebold Nixdorf, Incorporated Technology - Software - Application Investor Relations →
Diebold Nixdorf, Incorporated (DBD) closed at $77.86 as of 2026-05-01, trading 67.3% above its 200-week moving average of $46.53. The stock is currently moving closer to the line, down from 84.9% last week. The 14-week RSI sits at 58, indicating neutral momentum.
Over the past 14 weeks, up-weeks have carried more volume than down-weeks (1.66 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.
In 93 weeks of available data, DBD has never crossed below its 200-week moving average. This suggests the stock has maintained a strong long-term uptrend throughout its history.
With a market cap of $2.7 billion, DBD is a mid-cap stock. The company generates a free cash flow yield of 14.6%, which is notably high. Return on equity stands at 11.0%. The stock trades at 2.7x book value.
The company has been aggressively buying back shares, reducing its share count by 55.3% over the past three years.
Over the past 1.8 years, a hypothetical investment of $100 in DBD would have grown to $202, compared to $133 for the S&P 500. That represents an annualized return of 46.8% vs 16.9% for the index — confirming DBD as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been growing at a 49.2% compound annual rate, with 2 consecutive years of positive cash generation.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: DBD vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
Historical Touches
DBD has not crossed below its 200-week moving average in the available data (93 weeks).
Frequently Asked Questions
Is DBD below its 200-week moving average?
No. Diebold Nixdorf, Incorporated (DBD) is currently 67.3% above its 200-week moving average of $46.53. It would need to fall to $46.53 to cross below the line.
What is DBD's 200-week moving average price?
Diebold Nixdorf, Incorporated's 200-week moving average is $46.53 as of 2026-05-01. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
Is DBD a good value right now?
Here's what our data says about DBD as of 2026-05-01: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 58. Free cash flow yield is 14.6%. Return on equity is 11.0%. Price-to-book is 2.7x. This is not a buy or sell recommendation — always do your own research.
How does DBD compare to the S&P 500?
Over the past 1.8 years, $100 invested in DBD would have grown to $202, compared to $133 for the S&P 500. That's 46.8% annualized vs 16.9% for the index. DBD has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-05-01